Camrelizumab + gemcitabine + cisplatin (CAPTAIN-1st) — 1L recurrent/metastatic nasopharyngeal carcinoma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CAMRELIZUMAB` `DRUG-GEMCITABINE` `DRUG-CISPLATIN`

ID	`REG-NPC-GC-CAMRELIZUMAB`
Type	Regimen
Status	reviewed 2026-07-11 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-CAPTAIN-1ST-YANG-2021`

Notes

STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; dev-mode-exempted). CAPTAIN-1st (Yang Y et al., Lancet Oncol 2021): camrelizumab + gemcitabine/cisplatin vs placebo + gemcitabine/ cisplatin in treatment-naive recurrent/metastatic NPC. Approximate reported results (pending verification against primary source): mPFS ~9.7 vs ~6.9 months (HR ~0.55), ORR high in both arms (GP backbone alone is highly active in NPC). NOT FDA-approved — China/NMPA only, which is why toripalimab + GP (REG-NPC-GC-TORIPALIMAB) is the recommended default and this regimen is positioned as the equally- evidenced alternative. See IND-NPC-1L-METASTATIC-GC-PD1 known_controversies.

Used By

Indication

IND-NPC-1L-METASTATIC-GC-PD1 - IND-NPC-1L-METASTATIC-GC-PD1

Regimen

REG-NPC-GC-TORIPALIMAB - Toripalimab + gemcitabine + cisplatin (JUPITER-02) — 1L recurrent/metastatic nasopharynge...